Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Jan Astermark, Shashikant Apte, Chuhl Joo Lyu, Amalie Rhode Høgh Nielsen, Sonata Saulyte Trakymiene, Jay Jay Thaung Zaw, Huyen Tran, Jerzy Windyga, Hermann Eichler

Blood (2023) 142 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2023-173118

Published: 2023

Journal Articles

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Blood (2023) 142 (Supplement 1): 1055.

https://doi.org/10.1182/blood-2023-187624

Published: 2023

Journal Articles

Trial in Progress: An Open-Label, Multi-Center, First in Human, Phase 1/2a Trial to Evaluate the Safety and Preliminary Efficacy of Autologous Tolerogenic Dendritic Cells Ex Vivo Loaded with Recombinant Factor VIII (FVIII) in Adults with Congenital Hemophilia a (HA) with Neutralizing Antibodies to FVIII and Having Failed Immune Tolerance Induction (ITI)

Jan Astermark, Rolf Ljung, Eva Karlsson, Hanjing Xie

Blood (2022) 140 (Supplement 1): 12733–12734.

https://doi.org/10.1182/blood-2022-157250

Published: 2022

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

FVIII inhibitors: pathogenesis and avoidance

Jan Astermark

Blood (2015) 125 (13): 2045–2051.

https://doi.org/10.1182/blood-2014-08-535328

Published: 2015

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

Jan Astermark, Sharyne M. Donfield, Edward D. Gomperts, John Schwarz, Erika D. Menius, Anna Pavlova, Johannes Oldenburg, Bailey Kessing, Donna M. DiMichele, Amy D. Shapiro, Cheryl A. Winkler, Erik Berntorp

Blood (2013) 121 (8): 1446–1454.

https://doi.org/10.1182/blood-2012-06-434803

Published: 2013

Includes: Supplemental data

Journal Articles

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, Jan Astermark, Philip G. de Groot, Maurizio Margaglione, Arthur R. Thompson, Waander van Heerde, Jorien Boekhorst, Connie H. Miller, Saskia le Cessie, Johanna G. van der Bom

Blood (2012) 119 (12): 2922–2934.

https://doi.org/10.1182/blood-2011-09-379453

Published: 2012

Includes: Supplemental data

Journal Articles

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Lars Möllgård, Lars Nilsson, Lars Kjeldsen, Ingunn Dybedal, Inge Hogh Dufva, Hege Garelius, Jan Maxwell Norgaard, Olle Linder, Elisabeth Ejerblad, Jan Astermark, Eva Hellström-Lindberg

Blood (2009) 114 (22): 115.

https://doi.org/10.1182/blood.V114.22.115.115

Published: 2009

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.

Karin Wulff, Dr., Jan Astermark, MD, Prof., Dr., Falko F H Herrmann, Prof, (i.R.), Dr., Günther Auerswald, Dr., Winnie Schröder, Dr.

Blood (2009) 114 (22): 3481.

https://doi.org/10.1182/blood.V114.22.3481.3481

Published: 2009

Journal Articles

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland, Eva Hellström-Lindberg

Blood (2008) 112 (11): 223.

https://doi.org/10.1182/blood.V112.11.223.223

Published: 2008

Journal Articles

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg

Blood (2007) 110 (11): 818.

https://doi.org/10.1182/blood.V110.11.818.818

Published: 2007

Journal Articles

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Kathelijn Fischer, MD, PhD, Peter Collins, MD, Jan Astermark, MD, Victor S. Blanchette, MD, Sven Bjorkman, PhD, Myungshin Oh, PhD, Phillip Schroth, Sandor Fritsch, PhD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2007) 110 (11): 1145.

https://doi.org/10.1182/blood.V110.11.1145.1145

Published: 2007

Journal Articles

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

Jan Astermark, Johannes Oldenburg, Joyce Carlson, Anna Pavlova, Kaan Kavakli, Erik Berntorp, Ann-Kari Lefvert, for the MIBS Study Group

Blood (2006) 108 (12): 3739–3745.

https://doi.org/10.1182/blood-2006-05-024711

Published: 2006

Journal Articles

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Peter W. Collins, MD, Victor Blanchette, MD, Kathelijn Fischer, MD, Jan Astermark, MD, Phillip Schroth, Sandor Fritsch, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2006) 108 (11): 1041.

https://doi.org/10.1182/blood.V108.11.1041.1041

Published: 2006

Journal Articles

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

Katarina Steen Carlsson, PhD, Jan Astermark, PhD, MD, Sharyne M. Donfield, PhD, Erik Berntorp, MD

Blood (2006) 108 (11): 457.

https://doi.org/10.1182/blood.V108.11.457.457

Published: 2006

Journal Articles

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Jan Astermark, Sharyne M. Donfield, Donna M. DiMichele, Alessandro Gringeri, Steven A. Gilbert, Jennifer Waters, Erik Berntorp, for the FENOC Study Group

Blood (2006) 109 (2): 546–551.

https://doi.org/10.1182/blood-2006-04-017988

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

FVIII inhibitors: pathogenesis and avoidance

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only